168 related articles for article (PubMed ID: 25760768)
1. C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity.
Wiersma VR; de Bruyn M; Shi C; Gooden MJ; Wouters MC; Samplonius DF; Hendriks D; Nijman HW; Wei Y; Zhou J; Helfrich W; Bremer E
MAbs; 2015; 7(2):321-30. PubMed ID: 25760768
[TBL] [Abstract][Full Text] [Related]
2. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
3. TRAIL is involved in the tumoricidal activity of mouse natural killer cells stimulated by Newcastle disease virus in vitro.
Song DZ; Liang Y; Xiao Q; Yin J; Gong JL; Lai ZP; Zhang ZF; Gao LX; Fan XH
Anat Rec (Hoboken); 2013 Oct; 296(10):1552-60. PubMed ID: 23959779
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
Wu L; Parton A; Lu L; Adams M; Schafer P; Bartlett JB
Cancer Immunol Immunother; 2011 Jan; 60(1):61-73. PubMed ID: 20848094
[TBL] [Abstract][Full Text] [Related]
5. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
6. Cell surface delivery of TRAIL strongly augments the tumoricidal activity of T cells.
de Bruyn M; Wei Y; Wiersma VR; Samplonius DF; Klip HG; van der Zee AG; Yang B; Helfrich W; Bremer E
Clin Cancer Res; 2011 Sep; 17(17):5626-37. PubMed ID: 21753155
[TBL] [Abstract][Full Text] [Related]
7. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth.
Takeda K; Smyth MJ; Cretney E; Hayakawa Y; Yamaguchi N; Yagita H; Okumura K
Cell Immunol; 2001 Dec; 214(2):194-200. PubMed ID: 12088418
[TBL] [Abstract][Full Text] [Related]
8. Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice.
Ochi M; Ohdan H; Mitsuta H; Onoe T; Tokita D; Hara H; Ishiyama K; Zhou W; Tanaka Y; Asahara T
Hepatology; 2004 May; 39(5):1321-31. PubMed ID: 15122761
[TBL] [Abstract][Full Text] [Related]
9. E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells.
Yamauchi C; Fujii S; Kimura T; Kuwata T; Wada N; Mukai H; Matsumoto N; Fukayama M; Ochiai A
Int J Cancer; 2011 May; 128(9):2125-37. PubMed ID: 21387286
[TBL] [Abstract][Full Text] [Related]
10. Induction of porcine granulocyte-mediated tumor cytotoxicity by two distinct monoclonal antibodies against lytic trigger molecules (PNK-E/G7).
Wierda WG; Johnson BD; Dato ME; Kim YB
J Immunol; 1993 Dec; 151(12):7117-27. PubMed ID: 8258715
[TBL] [Abstract][Full Text] [Related]
11. [Progress of study on antitumor effects of antibody dependent cell mediated cytotoxicity--review].
Qu YH; Li Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1370-5. PubMed ID: 21129296
[TBL] [Abstract][Full Text] [Related]
12. [Newcastle disease virus enhances tumoricidal activity of mouse NK cells against mouse Novikoff hepatoma cells via up-regulating expression of TRAIL on the NK cells].
Song D; Liang Y; Fan X; Yin J; Gong J; Lai Z; Gao L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 May; 31(5):599-604. PubMed ID: 25940284
[TBL] [Abstract][Full Text] [Related]
13. Characterization and utilization of a monoclonal antibody inhibiting porcine natural killer cell activity for isolation of natural killer and killer cells.
Dato ME; Kim YB
J Immunol; 1990 Jun; 144(11):4452-62. PubMed ID: 1971298
[TBL] [Abstract][Full Text] [Related]
14. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A.
Liljefors M; Nilsson B; Hjelm Skog AL; Ragnhammar P; Mellstedt H; Frödin JE
Int J Cancer; 2003 Jul; 105(5):717-23. PubMed ID: 12740924
[TBL] [Abstract][Full Text] [Related]
15. [Current advances and expectations in tumor immunology].
Takeda K; Okumura K
Hum Cell; 2001 Sep; 14(3):159-63. PubMed ID: 11774735
[TBL] [Abstract][Full Text] [Related]
16. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
Liu Z; Lee FT; Hanai N; Smyth FE; Burgess AW; Old LJ; Scott AM
Cancer Immun; 2002 Oct; 2():13. PubMed ID: 12747758
[TBL] [Abstract][Full Text] [Related]
17. CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants.
Trebing J; El-Mesery M; Schäfer V; Weisenberger D; Siegmund D; Silence K; Wajant H
Cell Death Dis; 2014 Jan; 5(1):e1035. PubMed ID: 24481449
[TBL] [Abstract][Full Text] [Related]
18. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
[TBL] [Abstract][Full Text] [Related]
19. Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies.
Duong MN; Matera EL; Mathé D; Evesque A; Valsesia-Wittmann S; Clémenceau B; Dumontet C
MAbs; 2015; 7(1):192-8. PubMed ID: 25523586
[TBL] [Abstract][Full Text] [Related]
20. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
